Jump to:
Genflow Biosciences PLC Fundamentals
| Company Name | Genflow Biosciences PLC | Last Updated | 2024-12-20 |
|---|
| Industry | Biotechnology | Sector | Healthcare |
|---|
| Shares in Issue | 349.707 m | Market Cap | £5.16 m |
|---|
| PE Ratio | 0.00 | Dividend per Share | 0 |
|---|
| Dividend Yield | 0 | Dividend Cover | 0 |
|---|
| EPS | -£0.01 | EPS Growth (%) | 0 |
|---|
| PEG | 0 | DPS Growth (%) | 0 |
|---|
| Debt Ratio | 0 | Debt Equity Ratio | 0 |
|---|
| Asset Equity Ratio | 1.5741 | Cash Equity Ratio | 1.3280 |
|---|
| Quick Ratio | 2.3194 | Current Ratio | 2.73 |
|---|
| Price To Book Value | 6.0096 | ROCE | 0 |
|---|
Genflow Biosciences PLC Dividends
| Type | Ex-Date | Pay Date | Currency | Net Dividend | Year Total |
|---|
Genflow Biosciences PLC Company Financials
| Assets | 2023 | 2022 | 2021 |
|---|
| Tangible Assets | £3,394.00 | £2,351.00 | 0 |
| Intangible Assets | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 |
| Total Fixed Assets | £3,394.00 | £2,351.00 | 0 |
| Stocks | 0 | 0 | 0 |
| Debtors | £306,966.00 | £94,859.00 | £3,723.00 |
| Cash & Equivalents | £683,974.00 | £2.36 m | £224,004.00 |
| Other Assets | 0 | 0 | 0 |
| Total Assets | £1.07 m | £2.62 m | £276,551.00 |
| Liabilities | 2023 | 2022 | 2021 |
|---|
| Creditors within 1 year | £345,738.00 | £250,988.00 | £221,427.00 |
| Creditors after 1 year | 0 | 0 | 0 |
| Other Liabilities | 0 | 0 | 0 |
| Total Liabilities | £345,738.00 | £250,988.00 | £221,427.00 |
| Net assets | £725,915.00 | £2.37 m | £55,124.00 |
| Equity | 2023 | 2022 | 2021 |
|---|
| Called up share capital | £87,752.00 | £87,752.00 | £73,371.00 |
| Share Premium | £4.19 m | £4.19 m | £633,765.00 |
| Profit / Loss | -£1.63 m | -£1.34 m | -£988,195.00 |
| Other Equity | £725,915.00 | £2.37 m | £55,124.00 |
| Preference & Minorities | 0 | 0 | 0 |
| Total Capital Employed | £725,915.00 | £2.37 m | £55,124.00 |
| Ratios | 2023 | 2022 | 2021 |
|---|
| Debt Ratio | 0 | 0 | 0 |
| Debt-to-Equity | 0 | 0 | 0 |
| Assets / Equity | 1.5741 | 1.5741 | 1.5741 |
| Cash / Equity | 1.3280 | 1.3280 | 1.3280 |
| EPS | -£0.01 | £-0.00 | £-0.00 |
| Cash Flow | 2023 | 2022 | 2021 |
|---|
| Cash from operating activities | -£1.66 m | -£1.37 m | -£747,377.00 |
| Cashflow before financing | -£1.66 m | £2.13 m | £36,334.00 |
| Increase in Cash | -£1.66 m | £2.13 m | £224,004.00 |
| Income | 2023 | 2022 | 2021 |
|---|
| Turnover | 0 | 0 | 0 |
| Cost of sales | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 |
| Operating Profit | -£1.63 m | -£1.33 m | -£988,096.00 |
| Pre-Tax profit | -£1.63 m | -£1.34 m | -£988,195.00 |
Genflow Biosciences PLC Company Background
| Sector | Healthcare |
|---|
| Activities | Genflow Biosciences PLC is a preclinical biotechnology company focused on developing innovative biological interventions aimed at tackling the effects of aging, potentially slowing or halting the aging process and reducing the incidence ofage-related diseases and thereby increasing life span. The company is also focused on longevity and the development of therapies to counteract the effects of aging and diseases associated with age. |
|---|
| Latest Interim Date | 30 Sep 2024 |
|---|
| Latest Fiscal Year End Date | 7 May 2024 |
|---|
Genflow Biosciences PLC Directors
| Appointed | Name | Position |
|---|
| 2024-05-07 | Ms. Tamara L. Joseph | Non-Executive Director,Chairman |
| 2024-05-07 | Dr. Eric J. Leire | Executive Director,Chief Executive Officer |
| 2022-06-29 | Dr. Gabrielle Silver | Non-Executive Director |
| 2024-05-07 | Dr. Yassine Bendiabdallah | Non-Executive Director |
| 2022-06-29 | Professor Andrew J Scott | Non-Executive Director |
| 2024-05-07 | Dr. Peter King-Lewis | Non-Executive Director |
| 2024-05-07 | Dr. Guy-Charles Fanneau de la Horie | Non-Executive Director |
Genflow Biosciences PLC Contact Details
Genflow Biosciences PLC Advisors
